<DOC>
	<DOCNO>NCT01010308</DOCNO>
	<brief_summary>The purpose study explore efficacy safety Nadolol hemangioma infancy . The secondary objective ass feasibility conduct randomize controlled trial compare nadolol corticosteroid propranolol .</brief_summary>
	<brief_title>Nadolol Proliferating Infantile Hemangiomas</brief_title>
	<detailed_description>Systemic corticosteroid currently frequent use medication treatment problematic infantile hemangioma ( IH 's ) . Since June 2008 , systemic propranolol important addition therapeutic option problematic IH , allow decrease dependence systemic corticosteroid . So far , find excellent response propranolol minimal short-term side effect . Studies , compare nadolol propranolol child condition , suggest nadolol safer efficacious propranolol . In addition , good dose schedule less central nervous system ( CNS ) penetration , make suitable even patient suspect proven PHACES syndrome .</detailed_description>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Hemangioma , Capillary</mesh_term>
	<mesh_term>Port-Wine Stain</mesh_term>
	<mesh_term>Nadolol</mesh_term>
	<criteria>Intervention Group Infants age 1 month 1 year age head neck hemangiomas currently cause /or impend function loss ( e.g . vision , airway obstruction , feeding , etc ) , hemangiomas currently causing/or potential facial disfigurement . Historical Control Group Infants age 1 month 1 year age head neck hemangioma receive treatment systemic propranolol past 2 year Angiogenesis Marker Control Group Infants age 1 month 1 year attend dermatology clinic Intervention Group Patients PHACES syndrome ( prove ) suspect PHACES ( plaque like hemangioma await image ) . Children history hypersensitivity beta blocker Children personal history family history first degree relative asthma Children know renal impairment Children know cardiac condition may predispose heart block Personal history hypoglycemia Children medication may interact beta blocker Historical Control Group : No digital photography available document IHs progression Angiogenesis Marker Control Group : Children IH Children beta blocker systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>infantile hemangioma</keyword>
	<keyword>nadolol</keyword>
</DOC>